Golimumab

Indication

First line biologic for moderate to severe active ulcerative colitis after the failure of conventional therapy (NICE TA329) and LSCMMG Recommendation

NICE TA329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy

Red

Brand:

Simponi®

Nice TA:

329

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:

Gastro-intestinal system

Background

Golimumab is recommended by LSCMMG as first line treatment for adults with moderate to severe ulcerative colitis if conventional therapy hasn’t worked or isn’t suitable.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Gastroenterology Biologics Pathway Version 1.1

Decisions of Lancashire local decision making groups

BwD	BP	CSR	EL	FW	GP	MB	WL
Red	Red	Red	Red	Red	Red	Red	Red

What do the colours mean?

Last Updated: 01 - May - 2016